Project Grant R43AR082207
Award Date
9/7/23
Completion Date
8/31/24
Dollars Obligated
$296K
Similar Awards
This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...
This Project Grant award of $553,248 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant aims to investigate the role of the protein INPP5E in regulating macrophage function and its potential as a therapeutic target for rheumatoid arthritis (RA). The key objectives are to: 1) test the impact of INPP5E deletion or overexpression in macrophages on...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $295,294 to Biotherapeutics, Inc. for the development of a novel first-in-class topical immunoregulatory therapeutic for the treatment of plaque psoriasis. The key objectives are to: 1) evaluate the permeability and long-term stability of the topical drug product formulation, 2) compare the...
This Project Grant award in the amount of $506,085.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The objective of the award is to investigate obesity-induced inflammatory mediators as predictive biomarkers for response to biological therapies in patients with rheumatoid arthritis (RA). The research will utilize a multifaceted approach to develop 'biomarker...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $402,086 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Utah to develop joint-targeted antibody therapies for rheumatoid arthritis. The project, titled "Localization of Antibody Drugs to Arthritic Joints via Collagen Hybridization," aims to create new collagen-hybridizing peptide structures that can selectively deliver...
This SBIR Phase I award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to develop a novel topical therapeutic for the treatment of psoriasis. The key objectives are to: 1) characterize the therapeutic efficacy of the new treatment in a mouse model of psoriasis, 2) develop a topical drug product formulation and test its...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $393,412 Project Grant under CFDA 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research) to Vanderbilt University. The grant, which runs from September 17, 2024 to July 31, 2029, supports research to develop engineered cell therapies as agents for arthritis treatment. Key objectives include characterizing synthetic receptors to drive cartilage repair in an in vitro arthropathy model (Aim 1),...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Panorama Research Incorporated, doing business as Panorama Research Inc., a $275,765 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to develop an antibody-based therapy for reducing scarring and fibrosis following joint surgeries. The project aims to improve the delivery and tissue residence of a lead humanized antibody that inhibits collagen fibril formation, thereby...
This $139,895 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research at Brigham & Women's Hospital Inc. to investigate the role of "trained immunity" in linking inflammatory arthritis and cardiovascular disease development. The research aims to determine whether inflammatory responses in rheumatoid arthritis induce trained...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to establish a new "microphysiological joint-on-chip" system for the study of arthritic diseases and rapid testing of treatment candidates. The $618,629 award, effective from August 15, 2024 to July 31, 2029, will fund the development of human-derived biomaterial inks and...